Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.
Identifieur interne : 002D40 ( Main/Exploration ); précédent : 002D39; suivant : 002D41Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.
Auteurs : Alison R. Yung [Australie] ; Lisa J. Phillips ; Barnaby Nelson ; Shona M. Francey ; Hok Panyuen ; Magenta B. Simmons ; Margaret L. Ross ; Daniel Kelly ; Kathryn Baker ; G Paul Amminger ; Gregor Berger ; Andrew D. Thompson ; Annette Thampi ; Patrick D. McgorrySource :
- The Journal of clinical psychiatry [ 1555-2101 ] ; 2011.
Descripteurs français
- KwdFr :
- Adaptation sociale (MeSH), Adhésion au traitement médicamenteux (MeSH), Adolescent (MeSH), Adulte (MeSH), Assistance (MeSH), Association thérapeutique (MeSH), Facteurs de risque (MeSH), Femelle (MeSH), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Méthode en double aveugle (MeSH), Neuroleptiques (effets indésirables), Neuroleptiques (usage thérapeutique), Qualité de vie (psychologie), Rispéridone (effets indésirables), Rispéridone (usage thérapeutique), Résultat thérapeutique (MeSH), Schizophrénie (thérapie), Schizophrénie (traitement médicamenteux), Soutien social (MeSH), Thérapie cognitive (MeSH), Échelles d'évaluation en psychiatrie (MeSH).
- MESH :
- effets indésirables : Neuroleptiques, Rispéridone.
- psychologie : Qualité de vie.
- thérapie : Schizophrénie.
- traitement médicamenteux : Schizophrénie.
- usage thérapeutique : Neuroleptiques, Rispéridone.
- Adaptation sociale, Adhésion au traitement médicamenteux, Adolescent, Adulte, Assistance, Association thérapeutique, Facteurs de risque, Femelle, Humains, Jeune adulte, Mâle, Méthode en double aveugle, Résultat thérapeutique, Soutien social, Thérapie cognitive, Échelles d'évaluation en psychiatrie.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Cognitive Behavioral Therapy (MeSH), Combined Modality Therapy (MeSH), Counseling (MeSH), Double-Blind Method (MeSH), Female (MeSH), Humans (MeSH), Male (MeSH), Medication Adherence (MeSH), Psychiatric Status Rating Scales (MeSH), Quality of Life (psychology), Risk Factors (MeSH), Risperidone (adverse effects), Risperidone (therapeutic use), Schizophrenia (drug therapy), Schizophrenia (therapy), Social Adjustment (MeSH), Social Support (MeSH), Treatment Outcome (MeSH), Young Adult (MeSH).
- MESH :
- chemical , adverse effects : Antipsychotic Agents, Risperidone.
- chemical , therapeutic use : Antipsychotic Agents, Risperidone.
- drug therapy : Schizophrenia.
- psychology : Quality of Life.
- therapy : Schizophrenia.
- Adolescent, Adult, Cognitive Behavioral Therapy, Combined Modality Therapy, Counseling, Double-Blind Method, Female, Humans, Male, Medication Adherence, Psychiatric Status Rating Scales, Risk Factors, Social Adjustment, Social Support, Treatment Outcome, Young Adult.
Abstract
OBJECTIVE
Cognitive therapy and/or low-dose antipsychotic administered during the prodromal phase of schizophrenia may prevent or delay the onset of full-blown illness. However, it is unclear which of these treatments are most effective, how long treatment should be given, and whether effects will be sustained over a prolonged period.
METHOD
In order to examine these issues, we conducted a randomized controlled trial of cognitive therapy + risperidone; cognitive therapy + placebo; and supportive therapy + placebo in young people at ultra high risk for developing a psychotic disorder (that is, putatively prodromal). The main outcome was transition to psychotic disorder, with level of symptoms and functioning the secondary outcomes. This article reports the interim 6-month follow-up results. The study was conducted from August 2000 to May 2007.
RESULTS
Of a possible 464 eligible ultra high risk individuals, 115 were recruited to the randomized controlled trial (cognitive therapy + risperidone, n = 43; cognitive therapy + placebo, n = 44; and supportive therapy + placebo, n = 28). An additional 78 individuals agreed to follow-up assessments but not to randomization ("monitoring group," n = 78). At 6 months, 8 of the 115 participants (7.0%) and 4 of the monitoring group (5.1%) had developed psychotic disorder. There were no significant differences between the 3 randomized groups (log rank test, P = .92) or between all 4 groups (log rank test, P = .93). There was also no difference between the 4 groups in secondary measures, with all groups showing a reduction in symptoms and increased functioning.
CONCLUSIONS
Rates of transition to psychosis were lower than expected, particularly in the control supportive therapy + placebo group. This may have accounted for the negative finding, as the sample was therefore underpowered to find any difference between groups. Alternatively, it may be that all treatments were equally effective or equally ineffective at 6 months.
TRIAL REGISTRATION
http://www.anzctr.org.au Identifier: ACTRN012605000247673.
DOI: 10.4088/JCP.08m04979ora
PubMed: 21034687
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.</title><author><name sortKey="Yung, Alison R" sort="Yung, Alison R" uniqKey="Yung A" first="Alison R" last="Yung">Alison R. Yung</name><affiliation wicri:level="4"><nlm:affiliation>Orygen Research Centre and University of Melbourne, Department of Psychiatry, 35 Poplar Rd, Parkville 3052, Victoria, Australia. aryung@unimelb.edu.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Orygen Research Centre and University of Melbourne, Department of Psychiatry, 35 Poplar Rd, Parkville 3052, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Phillips, Lisa J" sort="Phillips, Lisa J" uniqKey="Phillips L" first="Lisa J" last="Phillips">Lisa J. Phillips</name></author><author><name sortKey="Nelson, Barnaby" sort="Nelson, Barnaby" uniqKey="Nelson B" first="Barnaby" last="Nelson">Barnaby Nelson</name></author><author><name sortKey="Francey, Shona M" sort="Francey, Shona M" uniqKey="Francey S" first="Shona M" last="Francey">Shona M. Francey</name></author><author><name sortKey="Panyuen, Hok" sort="Panyuen, Hok" uniqKey="Panyuen H" first="Hok" last="Panyuen">Hok Panyuen</name></author><author><name sortKey="Simmons, Magenta B" sort="Simmons, Magenta B" uniqKey="Simmons M" first="Magenta B" last="Simmons">Magenta B. Simmons</name></author><author><name sortKey="Ross, Margaret L" sort="Ross, Margaret L" uniqKey="Ross M" first="Margaret L" last="Ross">Margaret L. Ross</name></author><author><name sortKey="Kelly, Daniel" sort="Kelly, Daniel" uniqKey="Kelly D" first="Daniel" last="Kelly">Daniel Kelly</name></author><author><name sortKey="Baker, Kathryn" sort="Baker, Kathryn" uniqKey="Baker K" first="Kathryn" last="Baker">Kathryn Baker</name></author><author><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name></author><author><name sortKey="Berger, Gregor" sort="Berger, Gregor" uniqKey="Berger G" first="Gregor" last="Berger">Gregor Berger</name></author><author><name sortKey="Thompson, Andrew D" sort="Thompson, Andrew D" uniqKey="Thompson A" first="Andrew D" last="Thompson">Andrew D. Thompson</name></author><author><name sortKey="Thampi, Annette" sort="Thampi, Annette" uniqKey="Thampi A" first="Annette" last="Thampi">Annette Thampi</name></author><author><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21034687</idno><idno type="pmid">21034687</idno><idno type="doi">10.4088/JCP.08m04979ora</idno><idno type="wicri:Area/Main/Corpus">003022</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">003022</idno><idno type="wicri:Area/Main/Curation">003022</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">003022</idno><idno type="wicri:Area/Main/Exploration">003022</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.</title><author><name sortKey="Yung, Alison R" sort="Yung, Alison R" uniqKey="Yung A" first="Alison R" last="Yung">Alison R. Yung</name><affiliation wicri:level="4"><nlm:affiliation>Orygen Research Centre and University of Melbourne, Department of Psychiatry, 35 Poplar Rd, Parkville 3052, Victoria, Australia. aryung@unimelb.edu.au</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Orygen Research Centre and University of Melbourne, Department of Psychiatry, 35 Poplar Rd, Parkville 3052, Victoria</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Phillips, Lisa J" sort="Phillips, Lisa J" uniqKey="Phillips L" first="Lisa J" last="Phillips">Lisa J. Phillips</name></author><author><name sortKey="Nelson, Barnaby" sort="Nelson, Barnaby" uniqKey="Nelson B" first="Barnaby" last="Nelson">Barnaby Nelson</name></author><author><name sortKey="Francey, Shona M" sort="Francey, Shona M" uniqKey="Francey S" first="Shona M" last="Francey">Shona M. Francey</name></author><author><name sortKey="Panyuen, Hok" sort="Panyuen, Hok" uniqKey="Panyuen H" first="Hok" last="Panyuen">Hok Panyuen</name></author><author><name sortKey="Simmons, Magenta B" sort="Simmons, Magenta B" uniqKey="Simmons M" first="Magenta B" last="Simmons">Magenta B. Simmons</name></author><author><name sortKey="Ross, Margaret L" sort="Ross, Margaret L" uniqKey="Ross M" first="Margaret L" last="Ross">Margaret L. Ross</name></author><author><name sortKey="Kelly, Daniel" sort="Kelly, Daniel" uniqKey="Kelly D" first="Daniel" last="Kelly">Daniel Kelly</name></author><author><name sortKey="Baker, Kathryn" sort="Baker, Kathryn" uniqKey="Baker K" first="Kathryn" last="Baker">Kathryn Baker</name></author><author><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name></author><author><name sortKey="Berger, Gregor" sort="Berger, Gregor" uniqKey="Berger G" first="Gregor" last="Berger">Gregor Berger</name></author><author><name sortKey="Thompson, Andrew D" sort="Thompson, Andrew D" uniqKey="Thompson A" first="Andrew D" last="Thompson">Andrew D. Thompson</name></author><author><name sortKey="Thampi, Annette" sort="Thampi, Annette" uniqKey="Thampi A" first="Annette" last="Thampi">Annette Thampi</name></author><author><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name></author></analytic><series><title level="j">The Journal of clinical psychiatry</title><idno type="eISSN">1555-2101</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Cognitive Behavioral Therapy (MeSH)</term><term>Combined Modality Therapy (MeSH)</term><term>Counseling (MeSH)</term><term>Double-Blind Method (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Medication Adherence (MeSH)</term><term>Psychiatric Status Rating Scales (MeSH)</term><term>Quality of Life (psychology)</term><term>Risk Factors (MeSH)</term><term>Risperidone (adverse effects)</term><term>Risperidone (therapeutic use)</term><term>Schizophrenia (drug therapy)</term><term>Schizophrenia (therapy)</term><term>Social Adjustment (MeSH)</term><term>Social Support (MeSH)</term><term>Treatment Outcome (MeSH)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adaptation sociale (MeSH)</term><term>Adhésion au traitement médicamenteux (MeSH)</term><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Assistance (MeSH)</term><term>Association thérapeutique (MeSH)</term><term>Facteurs de risque (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Méthode en double aveugle (MeSH)</term><term>Neuroleptiques (effets indésirables)</term><term>Neuroleptiques (usage thérapeutique)</term><term>Qualité de vie (psychologie)</term><term>Rispéridone (effets indésirables)</term><term>Rispéridone (usage thérapeutique)</term><term>Résultat thérapeutique (MeSH)</term><term>Schizophrénie (thérapie)</term><term>Schizophrénie (traitement médicamenteux)</term><term>Soutien social (MeSH)</term><term>Thérapie cognitive (MeSH)</term><term>Échelles d'évaluation en psychiatrie (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term><term>Risperidone</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term><term>Risperidone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Neuroleptiques</term><term>Rispéridone</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Qualité de vie</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Quality of Life</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Schizophrenia</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Schizophrénie</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Schizophrénie</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Neuroleptiques</term><term>Rispéridone</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Cognitive Behavioral Therapy</term><term>Combined Modality Therapy</term><term>Counseling</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Medication Adherence</term><term>Psychiatric Status Rating Scales</term><term>Risk Factors</term><term>Social Adjustment</term><term>Social Support</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adaptation sociale</term><term>Adhésion au traitement médicamenteux</term><term>Adolescent</term><term>Adulte</term><term>Assistance</term><term>Association thérapeutique</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Résultat thérapeutique</term><term>Soutien social</term><term>Thérapie cognitive</term><term>Échelles d'évaluation en psychiatrie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>Cognitive therapy and/or low-dose antipsychotic administered during the prodromal phase of schizophrenia may prevent or delay the onset of full-blown illness. However, it is unclear which of these treatments are most effective, how long treatment should be given, and whether effects will be sustained over a prolonged period.</p></div><div type="abstract" xml:lang="en"><p><b>METHOD</b></p><p>In order to examine these issues, we conducted a randomized controlled trial of cognitive therapy + risperidone; cognitive therapy + placebo; and supportive therapy + placebo in young people at ultra high risk for developing a psychotic disorder (that is, putatively prodromal). The main outcome was transition to psychotic disorder, with level of symptoms and functioning the secondary outcomes. This article reports the interim 6-month follow-up results. The study was conducted from August 2000 to May 2007.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Of a possible 464 eligible ultra high risk individuals, 115 were recruited to the randomized controlled trial (cognitive therapy + risperidone, n = 43; cognitive therapy + placebo, n = 44; and supportive therapy + placebo, n = 28). An additional 78 individuals agreed to follow-up assessments but not to randomization ("monitoring group," n = 78). At 6 months, 8 of the 115 participants (7.0%) and 4 of the monitoring group (5.1%) had developed psychotic disorder. There were no significant differences between the 3 randomized groups (log rank test, P = .92) or between all 4 groups (log rank test, P = .93). There was also no difference between the 4 groups in secondary measures, with all groups showing a reduction in symptoms and increased functioning.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Rates of transition to psychosis were lower than expected, particularly in the control supportive therapy + placebo group. This may have accounted for the negative finding, as the sample was therefore underpowered to find any difference between groups. Alternatively, it may be that all treatments were equally effective or equally ineffective at 6 months.</p></div><div type="abstract" xml:lang="en"><p><b>TRIAL REGISTRATION</b></p><p>http://www.anzctr.org.au Identifier: ACTRN012605000247673.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21034687</PMID><DateCompleted><Year>2011</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>4</Issue><PubDate><Year>2011</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.</ArticleTitle><Pagination><MedlinePgn>430-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.08m04979ora</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Cognitive therapy and/or low-dose antipsychotic administered during the prodromal phase of schizophrenia may prevent or delay the onset of full-blown illness. However, it is unclear which of these treatments are most effective, how long treatment should be given, and whether effects will be sustained over a prolonged period.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">In order to examine these issues, we conducted a randomized controlled trial of cognitive therapy + risperidone; cognitive therapy + placebo; and supportive therapy + placebo in young people at ultra high risk for developing a psychotic disorder (that is, putatively prodromal). The main outcome was transition to psychotic disorder, with level of symptoms and functioning the secondary outcomes. This article reports the interim 6-month follow-up results. The study was conducted from August 2000 to May 2007.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of a possible 464 eligible ultra high risk individuals, 115 were recruited to the randomized controlled trial (cognitive therapy + risperidone, n = 43; cognitive therapy + placebo, n = 44; and supportive therapy + placebo, n = 28). An additional 78 individuals agreed to follow-up assessments but not to randomization ("monitoring group," n = 78). At 6 months, 8 of the 115 participants (7.0%) and 4 of the monitoring group (5.1%) had developed psychotic disorder. There were no significant differences between the 3 randomized groups (log rank test, P = .92) or between all 4 groups (log rank test, P = .93). There was also no difference between the 4 groups in secondary measures, with all groups showing a reduction in symptoms and increased functioning.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Rates of transition to psychosis were lower than expected, particularly in the control supportive therapy + placebo group. This may have accounted for the negative finding, as the sample was therefore underpowered to find any difference between groups. Alternatively, it may be that all treatments were equally effective or equally ineffective at 6 months.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">http://www.anzctr.org.au Identifier: ACTRN012605000247673.</AbstractText><CopyrightInformation>© Copyright 2011 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yung</LastName><ForeName>Alison R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Orygen Research Centre and University of Melbourne, Department of Psychiatry, 35 Poplar Rd, Parkville 3052, Victoria, Australia. aryung@unimelb.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phillips</LastName><ForeName>Lisa J</ForeName><Initials>LJ</Initials></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>Barnaby</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Francey</LastName><ForeName>Shona M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>PanYuen</LastName><ForeName>Hok</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Simmons</LastName><ForeName>Magenta B</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Margaret L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Amminger</LastName><ForeName>G Paul</ForeName><Initials>GP</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Gregor</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials></Author><Author ValidYN="Y"><LastName>Thampi</LastName><ForeName>Annette</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>McGorry</LastName><ForeName>Patrick D</ForeName><Initials>PD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003376" MajorTopicYN="N">Counseling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012944" MajorTopicYN="N">Social Support</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>09</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21034687</ArticleId><ArticleId IdType="doi">10.4088/JCP.08m04979ora</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><noCountry><name sortKey="Amminger, G Paul" sort="Amminger, G Paul" uniqKey="Amminger G" first="G Paul" last="Amminger">G Paul Amminger</name><name sortKey="Baker, Kathryn" sort="Baker, Kathryn" uniqKey="Baker K" first="Kathryn" last="Baker">Kathryn Baker</name><name sortKey="Berger, Gregor" sort="Berger, Gregor" uniqKey="Berger G" first="Gregor" last="Berger">Gregor Berger</name><name sortKey="Francey, Shona M" sort="Francey, Shona M" uniqKey="Francey S" first="Shona M" last="Francey">Shona M. Francey</name><name sortKey="Kelly, Daniel" sort="Kelly, Daniel" uniqKey="Kelly D" first="Daniel" last="Kelly">Daniel Kelly</name><name sortKey="Mcgorry, Patrick D" sort="Mcgorry, Patrick D" uniqKey="Mcgorry P" first="Patrick D" last="Mcgorry">Patrick D. Mcgorry</name><name sortKey="Nelson, Barnaby" sort="Nelson, Barnaby" uniqKey="Nelson B" first="Barnaby" last="Nelson">Barnaby Nelson</name><name sortKey="Panyuen, Hok" sort="Panyuen, Hok" uniqKey="Panyuen H" first="Hok" last="Panyuen">Hok Panyuen</name><name sortKey="Phillips, Lisa J" sort="Phillips, Lisa J" uniqKey="Phillips L" first="Lisa J" last="Phillips">Lisa J. Phillips</name><name sortKey="Ross, Margaret L" sort="Ross, Margaret L" uniqKey="Ross M" first="Margaret L" last="Ross">Margaret L. Ross</name><name sortKey="Simmons, Magenta B" sort="Simmons, Magenta B" uniqKey="Simmons M" first="Magenta B" last="Simmons">Magenta B. Simmons</name><name sortKey="Thampi, Annette" sort="Thampi, Annette" uniqKey="Thampi A" first="Annette" last="Thampi">Annette Thampi</name><name sortKey="Thompson, Andrew D" sort="Thompson, Andrew D" uniqKey="Thompson A" first="Andrew D" last="Thompson">Andrew D. Thompson</name></noCountry><country name="Australie"><region name="Victoria (État)"><name sortKey="Yung, Alison R" sort="Yung, Alison R" uniqKey="Yung A" first="Alison R" last="Yung">Alison R. Yung</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/PoplarV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= PoplarV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21034687
|texte= Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21034687" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a PoplarV1
| This area was generated with Dilib version V0.6.37. |  |